Mixed results for three of Bicycle Therapeutics plc’s zelenectide pevedotin development programs preceded a strong drop in the company’s stock. Bicycle shares (NASDAQ:BCYC) dropped 31.3% on Dec. 13 to ...

Smaller retailers that have already pre-ordered stock might be selling those models earlier, they added. Giving up on Trek, Saskia found a "really good value" bike on the website of the French ...